Nektar Therapeutics  

(Public, NASDAQ:NKTR)   Watch this stock  
Find more results for NKTR
+0.27 (2.23%)
Dec 2 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.90 - 12.60
52 week 10.52 - 19.98
Open 12.10
Vol / Avg. 1.13M/1.89M
Mkt cap 1.93B
P/E     -
Div/yield     -
EPS -1.22
Shares 152.84M
Beta 1.87
Inst. own 89%
Feb 27, 2017
Q4 2016 Nektar Therapeutics Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 16, 2016
Nektar Therapeutics at Jefferies Healthcare Conference
Nov 9, 2016
Nektar Therapeutics Society for Immunotherapy of Cancer (SITC)- Investor Call
Nov 3, 2016
Q3 2016 Nektar Therapeutics Earnings Call
Nov 3, 2016
Q3 2016 Nektar Therapeutics Earnings Release
Sep 27, 2016
Nektar Therapeutics Conference Call to Discuss New Clinical Collaboration with Bristol-Myers Squibb - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -118.96% -35.17%
Operating margin -90.55% -18.83%
EBITD margin - -7.16%
Return on average assets -39.04% -17.27%
Return on average equity - -379.68%
Employees 435 -
CDP Score - -


455 Mission Bay Blvd S
SAN FRANCISCO, CA 94158-2158
United States - Map
+1-415-4825300 (Phone)
+1-415-3395300 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company's pipeline consists of drug candidates for therapeutic areas, including oncology, pain, anti-infectives and immunology. The Company's drugs include MOVANTIK (naloxegol) tablets, MOVENTIG, AdYnoVATE, NKTR-102 (next-generation topoisomerase I inhibitor), BAY41-6551 (Amikacin inhale, formerly NKTR-061), NKTR-181 (orally-available mu-opioid analgesic molecule), NKTR-102, NKTR-214 and MoVAnTiK fixed-dose combinations (opioid/naloxegol combinations). Its drugs also include Neulasta (pegfilgrastim), PEGASYS (peginterferon alfa-2a), PEG-INTRON (peginterferon alfa-2b), Somavert (pegvisomant) and Macugen (pegaptanib sodium injection).

Officers and directors

Robert B. Chess Independent Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Howard W. Robin President, Chief Executive Officer, Director
Age: 63
Bio & Compensation  - Reuters
Gilbert M. Labrucherie J.D. Chief Financial Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
John L. Nicholson Chief Operating Officer, Senior Vice President
Age: 64
Bio & Compensation  - Reuters
Jillian B. Thomsen Senior Vice President - Finance, Chief Accounting Officer
Age: 50
Bio & Compensation  - Reuters
Stephen K. Doberstein Ph.D. Senior Vice President, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
Ivan P. Gergel M.D. Senior Vice President - Drug Development & Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Maninder Hora Ph.D. Senior Vice President - Pharmaceutical Development and Manufacturing Operations
Age: 62
Bio & Compensation  - Reuters
R. Scott Greer Independent Director
Age: 57
Bio & Compensation  - Reuters
Joseph J. Krivulka Independent Director
Age: 64
Bio & Compensation  - Reuters